Prof. Dr. Mehdi Zoghi

Çok Merkezli Ulusal ve Uluslararası Nitelikteki Araştırmalar:

• In Time-II, “Transvenous NPA for treatment of infarcting myocardium early, a double-blind comparison of single-bolus Lanoteplase vs accelerated Alteplase for the treatment of patients with acute myocardial infarction”, 1997.
• A to Z, “A multicenter, randomized, controlled, double-blind trial to investigate the clinical efficacy and tolerability of early treatment with Simvastatin 40 mg daily for 30 days followed by Simvastatin 80 mg daily there after in Tirofiban treated acute coronary syndrome patients who have been randomized to receive Enoxaparine or unfractionated Heparin in conjunction with Aspirin”, 1999.
• OVERTURE, “Omapatrilate versus Enalapril randomized trial of utility in reducing events”, 1999.
• A Double-blind randomized Phase III study to assess the Antihypertensive Efficacy and Safety of the Combination of candesartan Cilexetil 32 mg and Hydrochlorothiazide 25 mg in Hypertensive Adults, 2006.
• A comparison of Prasugrel and Clopidogrel in Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction who are medically managed, 2007.
• Magellan Study, Multicenter randomized, parallel Group Efficacy superiority study in hospitalized medically ill patients comparing rivaroxaban with enoxaparin.
• TRILOGY ACS study, A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed.
• ATLAS ACS 2 TIMI 51 study, A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or With Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes.
• ENGAGE AF TIMI 48 study, A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin in Subjects with Atrial Fibrillation - Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation.
• PRE-CONTROL Study Prevention and Control Program for Cardiovascular Diseases in Turkish Population.
• Elder-TURK: Epidemiology of Cardiovascular Disease in Elderly Turkish Population, ClinicalTrials.gov Identifier: NCT02347982. 2014 -2015
• Warfarin-TR: The AWAReness, EFficacy, SAfety and Time in Therapeutic Range of WarfarIN in TuRkish Population, 2014-2015
• Ege bölgesinde Akut Koroner Sendrom Geçiren olguların demografik bilgileri, tedavi ve sonlanım sonuçlarının değerlendirilmesi: Ege AKS çalışması 2014-2015
• NOAC-TR: Adherence to New Oral Anticoagulation Therapy in Turkey, ClinicalTrials.gov Identifier: NCT02480920. 2015-2016
• JournayHF-TR: Türkiye Popülasyonunda Kalp Yetersizliği Hastasının Hastane içi Yolculuğu (Patient Journey in Hospital with Heart Failure in Turkish Population: Journey HF-TR). 2015-2017.
• Endocarditis-TR: The treatment and prognosis of patients with suspected endocarditis who admitted to tertiary care centers in Turkey 2018
• MINOCA-TR: Myocardial Infarction with Non-obstructive Coronary Arteries in Turkish Population 2018.
• NOAC-TR: Drug adherence in patients taking new oral anticoagulation therapy in Turkey.
• Cardiovascular Risk Unawareness is Common in Individuals Admitting to Cardiology Outpatient Clinics In Turkey: the CVSCORE-TR study.
• MEDLIFE-TR: Medications and Lifestyles of Patients with Cardiovascular Risk Factors and/or Diseases In Turkish Population.
• BOOMERANG-ACS study: Demographic, Clinical Characteristics and Medications of Re-Hospitalized Patients for Acute Coronary Syndrome: A international multi-centre, observational study.
• PANAROMIC AF-TR: Patients in Turkey from RAMSES, NOAC-TR, WARFARIN-TR, AFTER Databases Comply with Phase 3 NOAC Trials?
• ARNi-TR: The Demographic, Clinical and Outcomes of Angiotensin Receptor-Neprilysin Inhibition in Turkish Population with Chronic Heart Failure and Reduced Ejection Fraction.
• LVH-TR Demographical and Clinical Profile of Patients with Left Ventricular Hypertrophy.
• NEBIVOLOL-TR The Safety and Tolerability of Nebivolol in Hypertensive Patients with Coronary Artery Disease and Left Ventricular Ejection Fraction ≥ 40% in Turkish Population.
• VACCINE-TR Observational Study on Pneumococcal Vaccination Status and Awareness in Patients Applying to Cardiology Clinics in Turkey
• PREVENTION-TR Secondary Prevention of Cardiovascular Diseases in Cardiology Outpatients